There is no FDA-approved ivermectin product for Demodex mites. The one approved topical ivermectin for the face — ivermectin cream 1%, sold as SOOLANTRA and as AB-rated generics — is indicated for something narrower. Its label's Indications and Usage section reads, in full: "SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea," per the DailyMed prescribing information (SPL version 8, effective 24 October 2024). If you want the labeling detail on the approved topical cream, that is where the indication, dosing and pharmacokinetics live — and Demodex is not among them.

For mites on the eyelids, the drug FDA has actually approved is not ivermectin at all. XDEMVY (lotilaner ophthalmic solution) 0.25% is approved under NDA 217603, and its label states: "XDEMVY is indicated for the treatment of Demodex blepharitis." Lotilaner is an isoxazoline, a different chemical family from the avermectins. Everything below reflects FDA records and labels verified on 28 September 2026.

Key takeaways

  • As of 28 September 2026, no FDA-approved ivermectin product in any dosage form carries a Demodex or blepharitis indication; the word Demodex appears zero times in the SOOLANTRA, SKLICE and STROMECTOL labels.
  • Ivermectin cream 1% is approved only for inflammatory lesions of rosacea, and its own label says the mechanism of that effect "is unknown."
  • The drug approved for Demodex blepharitis, XDEMVY, contains lotilaner — not ivermectin — and was approved on 24 July 2023.
  • Because no label addresses Demodex, there is no FDA-labeled "ivermectin dosage for Demodex." The only labeled doses are for rosacea lesions, head lice, strongyloidiasis and onchocerciasis.
  • Ivermectin cream is labeled "not for oral, ophthalmic, or intravaginal use," and the OTC ivermectin lotion tells users not to use it on lice in eyebrows or eyelashes.

What Demodex mites are and where they normally live

Pharmacist selecting plain unbranded cream tubes from wooden shelving in a small independent pharmacy, illustrating the prescription-only status of topical ivermectin cream.

Demodex folliculorum and Demodex brevis are microscopic mites that live in human hair follicles and sebaceous glands, most often on facial skin and at the base of the eyelashes. A 2025 review in International Journal of Molecular Sciences (PubMed 40282951) describes them as extremely common, with carriage increasing with age and the mere presence of mites not equating to disease — it is high mite density, in the authors' framing, that is associated with inflammatory conditions.

That distinction matters for everything that follows. "Having Demodex" is ordinary. The clinical questions are whether mite density is elevated and whether it is contributing to a specific condition — facial demodicosis, papulopustular rosacea, or Demodex blepharitis — and those are separate questions from what any drug is approved to treat.

What the approved topical ivermectin label is actually indicated for

Optometrist examining a patient's eyelid margins at a slit lamp during a check for Demodex blepharitis and lash-line collarettes.

SOOLANTRA (ivermectin) cream 1% was approved on 19 December 2014 under NDA 206255, held by Galderma Laboratories, L.P. FDA's approval letter states it "provides for the use of Soolantra (ivermectin) Cream, 1 % for treatment of inflammatory lesions of rosacea," and the Drugs@FDA record classifies the original submission as "Type 3 - New Dosage Form."

Label specifics, all from the current SPL: the cream is 1%, with each gram containing 10 mg of ivermectin, supplied in 30 g, 45 g and 60 g tubes. It is applied to affected areas of the face once daily, "a pea-size amount for each area of the face (forehead, chin, nose, each cheek) that is affected," spread thin, avoiding eyes and lips. The label states plainly that the cream "is not for oral, ophthalmic, or intravaginal use." Contraindications are listed as "None." The most common adverse reactions in controlled trials, at an incidence of 1% or less, were skin burning sensation and skin irritation.

One header line confuses readers regularly: the SPL reads "Initial U.S. Approval: 1996." That refers to the first US approval of the ivermectin molecule (the oral tablet), not to the cream, which was approved in 2014. The same 1996 line appears on the generic cream labels.

Three generic ivermectin cream 1% applications are listed in the FDA Orange Book data files (file dated 11 September 2026): Teva ANDA 210019 (approved 13 September 2019), Padagis Israel ANDA 210225 (13 April 2020) and Zydus Lifesciences ANDA 215210 (2 August 2022), all AB-rated and prescription-only. The Padagis generic label carries the identical rosacea-only indication. Mayne Pharma additionally markets an authorized generic under Galderma's NDA 206255, as the approval element of its own SPL shows.

FDA-approved products relevant to mites on human skin and eyelids, verified 28 September 2026
Product Active ingredient / strength Application Indication as the label words it Rx / OTC Label mentions Demodex?
SOOLANTRA cream Ivermectin 1% (10 mg/g) NDA 206255, approved 19 Dec 2014 "inflammatory lesions of rosacea" Rx No — zero occurrences
SKLICE lotion Ivermectin 0.5% NDA 202736, approved 7 Feb 2012; OTC switch 27 Oct 2020 Use: "treats head lice" OTC No — zero occurrences
STROMECTOL tablet Ivermectin 3 mg NDA 050742, original approval 22 Nov 1996 Intestinal strongyloidiasis; onchocerciasis Rx No — zero occurrences
XDEMVY eye drops Lotilaner 0.25% (2.5 mg/mL) NDA 217603, approved 24 Jul 2023 "treatment of Demodex blepharitis" Rx Yes — it is the indication

Why that indication is not the same as treating Demodex density

Customer at a pharmacy prescription pick-up window, reflecting that oral ivermectin tablets remain prescription-only in the United States.

Two things in the cream's label do the work here. First, section 12.1 states: "The mechanism of action of SOOLANTRA cream in treating rosacea lesions is unknown." The popular explanation that the cream works by killing Demodex is not on the label. Second, the words scabies, lice, pediculosis, Demodex, mite and blepharitis appear zero times anywhere in the full SPL, including Indications, Dosage, Clinical Studies and Mechanism of Action.

The trials behind the approval were not mite-count trials. Per section 14, the cream was studied in two identically designed randomized, double-blind, vehicle-controlled trials in 1,371 subjects aged 18 and older, treated once daily at bedtime for 12 weeks, with co-primary endpoints of Investigator Global Assessment success and absolute change in inflammatory lesion counts at Week 12. At Week 12, 38.4% of cream subjects were clear or almost clear versus 11.6% on vehicle in Study 1, and 40.1% versus 18.8% in Study 2. Mean inflammatory lesion reduction was 20.5 lesions (64.9%) versus 12.0 (41.6%) in Study 1, and 22.2 (65.7%) versus 13.4 (43.4%) in Study 2. No mite-density endpoint appears in the label. An approval for rosacea lesions is therefore not an approval for reducing Demodex density, and FDA labeling does not assert the latter.

Demodex blepharitis: the eyelid condition and the drug now approved for it

Plain unlabeled tubes and jars from an online order spread on a kitchen table, representing products marketed for Demodex without FDA approval.

Demodex blepharitis is inflammation of the eyelid margin associated with mites at the lash base; the collarettes (cylindrical cuffs) at the lash root are the sign clinicians count. XDEMVY (lotilaner ophthalmic solution) 0.25% was approved on 24 July 2023 under NDA 217603, held by Tarsus Pharmaceuticals, and FDA's approval letter states it "provides for the use of Xdemvy (lotilaner ophthalmic solution), 0.25% for the treatment of Demodex blepharitis." Drugs@FDA classifies it as "Type 1 - New Molecular Entity" with standard review.

Its label describes lotilaner as "a member of the isoxazoline family of compounds" and a "GABA-gated chloride channel inhibitor selective for mites," not an inhibitor of mammalian GABA-mediated chloride channels at concentrations up to 30 µM. Dosing is one drop in each eye twice daily, approximately 12 hours apart, for 6 weeks. Contact lenses should be removed before instillation and may be reinserted 15 minutes afterward. The most common ocular adverse reaction was instillation site stinging and burning, reported in 10% of patients. Safety and effectiveness below age 18 have not been established, and there is no approved generic — lotilaner appears as a single row in the September 2026 Orange Book file.

Efficacy came from two 6-week randomized, multicenter, double-masked, vehicle-controlled studies, Saturn-1 and Saturn-2, in 833 patients total, 415 of whom received XDEMVY, randomized 1:1. The primary endpoint was reduction of collarettes to no more than 2 per upper lid at Day 43, met with p<0.01 in each study; the percentages achieving it are shown only in figures, not in quotable label text. Secondary results differed between trials: mite eradication (0 mites per lash) at Day 43 was 68% versus 17% on vehicle in Saturn-1 and 50% versus 14% in Saturn-2; erythema cure was 19% versus 7% and 30% versus 9%, all p<0.01.

One commonly repeated line we could not confirm: the manufacturer and several journal reviews describe XDEMVY as the first FDA-approved treatment for Demodex blepharitis, but we could not verify the word "first" in any primary FDA document, so treat it as a company and journal characterization rather than a regulatory fact.

Acne versus rosacea: why the labels differ and why the confusion persists

The cream's indication is the inflammatory lesions of rosacea — the papules and pustules — not rosacea generally, not flushing, and not erythema, which was not a co-primary endpoint. Those papules and pustules look like acne, and older terminology called the condition "acne rosacea." That resemblance is most of why "ivermectin for acne" circulates.

Regulatorily, the picture is simple. Only three human ivermectin dosage forms have FDA approval in the United States — oral tablet, topical cream and topical lotion — and their labeled indications are inflammatory lesions of rosacea, head lice, intestinal strongyloidiasis and onchocerciasis. Acne vulgaris is not among them, in either the brand or the generic labeling. A clinician may still make an off-label judgment; that judgment is theirs to explain, and it is not an FDA finding of effectiveness.

What the oral tablet's label says, and what it does not cover

STROMECTOL is approved under NDA 050742, held by Merck Sharp & Dohme, with an original approval of 22 November 1996 as a Type 1 New Molecular Entity under priority review; the 3 mg tablet marketed today carries an Orange Book approval date of 8 October 1998. Its current label is the September 2024 revision, it is "Rx only," and its indications are limited to strongyloidiasis of the intestinal tract and onchocerciasis. Scabies, rosacea, lice and Demodex appear nowhere in it. If you want the full picture of what the oral label covers, that is the boundary.

The labeled doses are single oral doses tied to those two infections: approximately 200 mcg/kg for strongyloidiasis and approximately 150 mcg/kg for onchocerciasis, each with its own weight-band table (strongyloidiasis runs 1 tablet at 15–24 kg to 5 tablets at 66–79 kg; onchocerciasis runs 1 tablet at 15–25 kg to 4 tablets at 65–84 kg). Tablets are to be taken on an empty stomach with water — a 30 mg dose after a high-fat meal produced roughly a 2.5-fold increase in bioavailability. Plasma half-life is about 18 hours. The only labeled drug interaction is rarely reported increased INR with warfarin; the only contraindication is hypersensitivity to any component. The label warns that neurotoxicity, including altered consciousness, confusion, disorientation and death, has been reported, including in patients without onchocerciasis, and states that ivermectin "should not be used during pregnancy since safety in pregnancy has not been established." Safety and effectiveness in pediatric patients under 15 kg have not been established. There is no labeled oral ivermectin dose for Demodex of any kind.

Seven states have enacted laws changing how adults obtain oral ivermectin — Arkansas (no in-force date recorded) and Idaho (in force 14 April 2025) by statutory OTC status, Iowa (1 July 2026) through pharmacies, Louisiana (20 June 2025) by standing order, Missouri (28 August 2026) and Texas (4 December 2025) by pharmacist protocol, and Tennessee (22 April 2022) by collaborative pharmacy agreement. Two of the seven put nobody between the patient and the product (Arkansas and Idaho); the other five route the decision through a pharmacist or a pharmacy. A separate North Dakota law (in force 15 November 2021) is often counted alongside these, but it is not an access law: it shields the prescriber or pharmacist from discipline or liability and opens no new route for a patient, who still needs a prescription. None of these laws adds an indication. Access and approval are different things.

Diagnosis: why this is a clinician's call and what they look for

Nothing about mites on skin or lids is reliably self-diagnosable. Facial demodicosis, papulopustular rosacea, seborrheic dermatitis and acne overlap visually, and dermatologists distinguish them partly by examination and partly by sampling techniques such as standardized skin surface biopsy or scraping to estimate mite density — methods the 2025 Demodex review notes vary between studies, which is one reason published mite-density figures are hard to compare.

For eyelids, the examination is a slit-lamp look at the lash line for collarettes; that is the sign the XDEMVY trials counted, and mite density was assessed as mites per lash. This is work for an optometrist or ophthalmologist, not a bathroom mirror — and the approved ivermectin cream is explicitly labeled "not for oral, ophthalmic, or intravaginal use," so eyelid margins are outside its instructions entirely.

What the case literature reports, with its limitations stated

Published research on ivermectin and Demodex exists, but it sits outside FDA labeling and is mostly small and uncontrolled. A 2025 systematic review and meta-analysis in Parasite Epidemiology and Control (PMC12523798, PubMed entry dated 23 September 2025) pooled a small set of studies of topical ivermectin 1% and reported reductions in mite burden, while the authors themselves note small sample sizes and high heterogeneity arising from differing diagnostic methods, baseline mite densities, treatment durations and follow-up, and caution that the findings require careful interpretation.

A narrative review of ivermectin in Demodex-associated blepharitis in Eye & Contact Lens (PubMed 42381191) summarizes topical and oral use and reports generally lower mite density and improved symptoms in the studies it gathered — but a narrative review is a summary of heterogeneous reports, not a controlled trial, and it does not create an approved indication. A 2026 case series in Clinical Insights in Eyecare describing nonprescription topical ivermectin for Demodex-associated blepharitis is, by design, uncontrolled and unblinded; case series can generate hypotheses but cannot establish effect size or safety. Note also what the OTC lotion's own Drug Facts say: do not use on lice in eyebrows or eyelashes, and "See a doctor if lice are present in these areas."

Products marketed for Demodex that have no FDA approval behind them

Several categories circulate, and none of them is an FDA-approved Demodex treatment.

Topical ivermectin listings filed outside any approved application

DailyMed carries ivermectin 0.5% topical listings filed as OTC monograph drugs rather than under an approved NDA or ANDA, from firms including Guangxi Keyun E-commerce, Yunqi Cosmetics, Shenzhen Xuyan Technology, Shenzhen Zhenshangzekai Technology and Guangzhou Yusong Fine Chemicls; the approval element of one such SPL reads "OTC Monograph Drug," not an approved application. A DailyMed listing is a company submission, not an FDA approval.

Cosmetic eyelid cleansers and botanical washes

Tea-tree and similar lid-hygiene products are typically sold as cosmetics. As FDA explains on its cosmetics labeling claims page, the agency does not approve cosmetic claims before marketing and has issued warning letters to firms making unapproved drug claims for cosmetics. Marketing language about killing mites is not evidence that a product does so.

Animal ivermectin products

Ivermectin pastes, pour-ons, drenches and injectables sold for horses, cattle and other animals are labeled for animal use only and are not approved for people. Their concentrations and excipients are designed for animal dosing and differ entirely from the human tablet, which contains microcrystalline cellulose, pregelatinized starch, magnesium stearate, butylated hydroxyanisole and anhydrous citric acid powder. FDA has also stated, in its consumer update Ivermectin and COVID-19 (content current as of 5 April 2024), that it "has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans or animals" — a reminder that animal products carry neither human approval nor human dosing instructions for any indication, including Demodex.

Frequently asked questions

Is there any FDA-approved ivermectin for Demodex mites?

No. As of 28 September 2026, no FDA-approved ivermectin product carries a Demodex or blepharitis indication, and the word Demodex appears zero times in the SOOLANTRA, SKLICE and STROMECTOL labels. The only FDA-approved product with a Demodex indication is XDEMVY, which contains lotilaner.

What is the ivermectin dosage for Demodex?

There is no FDA-labeled ivermectin dose for Demodex, because no label addresses it. The labeled regimens are: cream 1% once daily to affected facial areas for inflammatory lesions of rosacea; lotion 0.5% left on dry hair and scalp for 10 minutes as a single application for head lice; and single oral doses of approximately 200 mcg/kg (strongyloidiasis) or 150 mcg/kg (onchocerciasis). Any other use is an off-label decision for a prescriber.

Can topical ivermectin cream be used on the eyelids?

The label states the cream "is not for oral, ophthalmic, or intravaginal use," and its dosing instructions say to avoid the eyes and lips. Eyelid symptoms warrant an eye examination.

Does the OTC ivermectin lotion treat eyelash mites?

Its labeled Use is "treats head lice," and the Drug Facts panel instructs users not to apply it near the eyes or on lice in eyebrows or eyelashes, advising a doctor visit instead. The lotion became OTC on 27 October 2020 through a complete prescription-to-OTC switch under NDA 202736/S-006 — an approved-NDA route, not an OTC monograph.

Is ivermectin approved for acne?

No. Across all approved human ivermectin dosage forms — tablet, cream and lotion — the labeled indications are inflammatory lesions of rosacea, head lice, intestinal strongyloidiasis and onchocerciasis. Acne vulgaris is not among them.

If my state made ivermectin available without a prescription, does that mean it works for Demodex?

No. State access laws change how a product may be dispensed within that state; they do not alter FDA-approved indications or add evidence of effectiveness.

Sources